Your GP ran the blood panel. Ferritin, thyroid, B12 — all within range. She was thorough. She had eight minutes. The conclusion was that nothing medically actionable had been found, which is a different thing from saying the problem has no addressable cause.

The NHS can rule out a deficiency. It is not designed to treat female-pattern follicular thinning. That is not a criticism — it is a rationing decision that makes sense for a public system. But the gap between "nothing is wrong on paper" and "something is visibly happening to my hair" is real, and it is not a gap the GP appointment was designed to close.

The women who stay stuck longest are those who take normal bloods as proof that nothing can be done. They are two different things.

The private trichologist earns her fee. She will identify menopausal androgenetic thinning, explain that falling oestrogen allows local DHT activity to rise, and describe how that shortens the growth phase until individual follicles go quiet. That diagnosis is accurate and useful.

What she typically offers next is minoxidil and an in-house tonic. The diagnosis was worth having. The route built around it leads straight back to the products that were not working before. The £200 buys a name for the mechanism, not an exit from the cycle.

This matters because the mechanism she named — local DHT pressure on the scalp — is, on its own, addressable. The address just has to be specific and topical, which is not what the private-clinic upsell is built around.

When you take a DHT-blocking supplement — biotin, Nutrafol, marine collagen — it enters your stomach, goes to your liver, and disperses through your entire bloodstream. Your vital organs take priority. By the time a fraction of anything reaches your scalp, the concentration is negligible.

You are trying to water a plant by drinking a glass of water. A local scalp problem needs a local solution. Swallowing the mechanism is not the same as delivering it to the tissue where the problem is happening.

This is not a criticism of supplements in general. It is an explanation of why the hair-specific ones routinely underperform compared to their ingredient lists: none of that chemistry ever arrives at the follicle in a useful dose.

As oestrogen falls through perimenopause and menopause, local DHT activity at the scalp rises. DHT shortens the anagen phase — the growth window — and the follicle spends progressively less time producing hair and more time dormant. The hair you see becoming finer is not a dead follicle. It is a living one that has been chemically compressed.

"Silenced, not dead" changes the practical question. A dead follicle offers nothing to work with. A dormant one, still biologically active, can resume a normal growth cycle when the local pressure that is silencing it is interrupted. That interruption is possible. It does not run through the NHS. It does not require a prescription.

Most women who have been told to "manage expectations" were given that advice by a system that had no mechanism to intervene — not by a biological fact about their own follicles.

Minoxidil is a drug, not a cosmetic. It works for some women — and it commits you to using it indefinitely. Stop, and many users experience a rebound shed that leaves them worse off than they started. That is not a side effect most GPs explain at the point of prescription.

The case for starting minoxidil before exhausting scalp-targeted, hormone-aware alternatives is not clear. Many women find that a topical intervention built around the actual mechanism — local DHT, reduced microcirculation, compressed anagen — stabilises their hair without that commitment.

The question is not whether minoxidil works. It is whether a mechanism-matched topical should come first. Most women who find it does were glad they tried in that order.

Menopausal hair operates on a biological timeline that product marketing never mentions. The hair cycle at this stage takes three months minimum to respond to any topical intervention. A thickening shampoo used for ten days and abandoned has not failed. It has not had time to do anything.

Cycling between products quarterly is how women spend £600 and conclude that nothing works — when the correct conclusion is that nothing was given enough time to work. The assessment window and the shopping window are not the same length, and the industry benefits from that confusion.

Pick one scalp-level treatment built around the right mechanism. Give it twelve weeks. Count the drain. Then decide.

It is not vanity. The hair that is thinning was part of how you have always recognised yourself. The overhead light you started avoiding, the ponytail you stopped wearing, the photograph you turned down — those are not cosmetic inconveniences. They are a life reorganised around a gap the system named and never resolved.

It is not your fault that the GP had no treatment to offer. It is not your fault that the private specialist's route looped back to the same products. The pathway failed to solve it. You are not the failed variable.

Mellenza Hair Growth Spray is the topical intervention built around the mechanism both routes confirmed: local DHT pressure, compressed anagen, reduced follicle circulation. 30 seconds in the evening, applied directly to the scalp.

Caffeine interrupts local DHT activity at the follicle bulb — the chemistry that has been shortening your growth phase. Polygonum multiflorum has been studied for its effect on follicle proliferation in the dermal papilla, helping dormant follicles resume a normal growth cycle. Arginine supports the microcirculation oestrogen decline reduces around the follicle. Biotin applied topically reaches the follicle directly, at a concentration oral supplements never deliver through the digestive route. Ginger extract supports anti-inflammatory scalp comfort and helps the other actives absorb more deeply.

Not a shampoo. Not a volumiser. Not a supplement. A topical serum built around the local mechanism — because a local problem requires a local solution.